The NMDA antagonist memantine impairs classical eyeblink conditioning in humans

Neurosci Lett. 1997 Mar 7;224(1):57-60. doi: 10.1016/s0304-3940(97)13452-8.

Abstract

The present study investigated the effects of a single oral dose (30 mg) of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine on memory and learning in human subjects. Sixteen male healthy volunteers participated in a double blind placebo controlled study. There were no significant effects of memantine on mood, attention or immediate and delayed verbal and visuospatial memory. Memantine did, however, delay the acquisition of classical eyeblink conditioning and reduced the overall frequency of conditioned responses without affecting reflex or spontaneous eyeblinks. These findings are compatible with the higher affinity of memantine to cerebellar as compared to forebrain tissue and demonstrate the dissociability of different memory systems by pharmacological tools.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Affect / drug effects
  • Blinking / drug effects*
  • Conditioning, Classical / drug effects*
  • Double-Blind Method
  • Excitatory Amino Acid Antagonists / pharmacology*
  • Humans
  • Learning / drug effects
  • Male
  • Memantine / pharmacology*
  • Memory / drug effects
  • N-Methylaspartate / antagonists & inhibitors*

Substances

  • Excitatory Amino Acid Antagonists
  • N-Methylaspartate
  • Memantine